Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Stem Cell Transplant in Patients With Aggressive Non Hodgkin's Lymphoma.

NCT01296256 is registered in ClinicalTrials.gov with Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea as lead sponsor.

NCT NCT01296256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01296256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Stem Cell Transplant in Patients With Aggressive Non Hodgkin's Lymphoma.
Lead sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
November 30, 2015
Enrollment
60 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non hodgkin's lymphoma, autologous stem cell transplant, bendamustine, conditioning therapy